<DOC>
	<DOCNO>NCT01870284</DOCNO>
	<brief_summary>This study ass safety efficacy ixekizumab ( LY2439821 ) compare placebo participant active AS .</brief_summary>
	<brief_title>Study Ixekizumab Participants With Active Ankylosing Spondylitis ( AS )</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis moderate severe AS prior document radiologic evidence ( Xray ) fulfil Modified New York criterion AS ( 1984 ) Have active AS define Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) ≥4 spinal pain ( back pain ) score ≥4 numeric rating scale ( NRS ) Participants nonsteroidal antiinflammatory drug ( NSAIDs ) inadequate response Participants regularly take NSAIDs cyclooxygenase2 ( COX2 ) inhibitor part AS therapy require stable dose Participants tumor necrosis factor alpha ( TNF ) inhibitor ( one ) must experience inadequate response Total duration prior therapy ( NSAIDs and/or adequate physical therapy ) least 12 week Men must agree use reliable method birth control remain abstinent study Women must agree use reliable birth control remain abstinent study least 12 week stop treatment Participants total ankylosis spine Prior current treatment adalimumab Participants previously treat biological immunomodulating agent except target TNF Evidence active inflammatory arthritic syndrome spondyloarthropathies ankylose spondylitis Have participate study interleukin 17 ( IL17 ) antagonist , include ixekizumab Serious disorder illness ankylose spondylitis Serious infection within last 3 month Breastfeeding nursing ( lactate ) woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>